Trial Profile
Real world outcomes in patients with newly diagnosed multiple myeloma treated with triplet regimens lenalidomide, bortezomib and dexamethasone and cyclophosphamide, bortezomib and dexamethasone: a retrospective, observational study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 Dec 2017
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Cyclophosphamide (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 28 Dec 2017 New trial record
- 12 Dec 2017 Results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology